Hologic picks up medical aesthetics player Cynosure in $1.6B+ deal

Hologic is well-known for its breast imaging devices. (Hologic)

Diagnostics player Hologic is diving into medical aesthetics with an acquisition of Cynosure worth approximately $1.65 billion.

The all-cash transaction is expected to close in March or April. It will be funded with cash on hand, which includes proceeds from the $1.85 billion divestiture of its blood-screening business to longtime partner Grifols.

The deal will serve as Hologic’s entry into the medical aesthetics space—which includes noninvasive body-contouring devices—while also expanding Cynosure’s market reach, the companies said in a statement.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"We had identified medical aesthetics as an attractive and complementary growth opportunity through our strategic planning process, and are pleased to have agreed to acquire Cynosure, the best-in-class company in the space,” said Hologic CEO Steve MacMillan in the statement.

Hologic’s announcement comes a day after Allergan announced it would pick up Zeltiq, which markets the fat-freezing CoolSculpting system, to boost its aesthetics offerings.

In addition to body-contouring systems, Cynosure markets devices for hair removal, tattoo removal and the treatment of surgical and acne scars. The company posted $433.5 million in revenues for 2016, a 28% leap from its sales haul the previous year.

"Strategically, this deal enables Cynosure to further capitalize on growth opportunities in the core and non-core aesthetic market, rapidly strengthens our position in women's health—where Hologic has a leading commercial presence—and accelerates our R&D initiatives," said Cynosure CEO Michael Davin in the statement.

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.